Supplementary Table 1. Cox regression analysis for the prediction of ch-ALL patients’ DFS and CSS according to BCL2 and BAX expression at diagnosis

/ Univariate analysis
/ Disease-free survival (DFS) / Cancer-specific survival (CSS)

Covariant

/ HRa / 95% CIb / p-valuec / HRa / 95% CIb / p-valuec
BCL2
High expression
Low expression /
1.00
3.903 /
1.414-10.77 /
0.009 /
1.00
3.159 /
0.789-12.64 /
0.104
BAX
High expression
Low expression /
1.00
4.640 /
1.046-20.57 /
0.043 /
1.00
46.99 /
0.137-16110 /
0.196
BCL2 and BAX
low expression
No
Yes / 1.00
4.700 / 1.703-12.97 / 0.003 / 1.00
3.704 / 0.926-14.82 / 0.064
BM blast percentage
<5% (M1)
>5% (M2-M3) / 1.00
2.461 / 1.465-4.134 / 0.001 / 1.00
2.082 / 1.016-4.267 / 0.045
MRD
Negative
Positive / 1.00
4.856 / 1.211-19.50 / 0.026 / 1.00
4.491 / 0.259-23.99 / 0.430
Immunophenotype
B-lineage ALL
T-lineage ALL /
1.00
1.547 /
0.821-2.914 /
0.177 /
1.00
2.314 /
1.129-4.743 /
0.022
WBC count
<50,000 cells/μl
≥50,000 cells/μl / 1.00
1.259 / 0.355-4.464 / 0.722 / 1.00
2.958 / 0.706-12.39 / 0.138
Risk group
Low or Intermediate
High / 1.00
1.958 / 1.103-3.473 / 0.022 / 1.00
1.855 / 0.833-4.133 / 0.131
t(12;21)(p13;q22) / 0.158 / 0.021-1.203 / 0.075 / 0.028 / <0.001-16.51 / 0.273
High hyperdiploidy / 1.168 / 0.329-4.144 / 0.810 / 1.541 / 0.311-7.635 / 0.597
Age
1-10 years
≥10 years / 1.00
4.146 / 1.501 - 11.45 / 0.006 / 1.00
10.61 / 2.139-52.63 / 0.004
Gender
Female
Male /
1.00
1.290 /
0.441-3.775 / 0.642 /
1.00
1.086 /
0.259-4.544 / 0.910
/ Multivariate analysisd
/ Disease-free survival (DFS) / Cancer-related survival (CRS)

Covariant

/ HRa / 95% CIb / p-valuec / HRa / 95% CIb / p-valuec
BCL2
High expression
Low expression /
1.00
1.350 /
0.307-5.941 /
0.691 /
1.00
0.535 /
0.044-6.513 /
0.624
BAX
High expression
Low expression / 1.00
1.805 /
0.308-10.57 /
0.513 / 1.00
1.085 /
0.093-12.70 /
0.948
BCL2 and BAX
low expression
No
Yes / 1.00
1.565 / 0.371-6.600 / 0.542 / 1.00
0.675 / 0.071-6.441 / 0.733

a Hazard Ratio

b 95% Confidence Intervals

c Test for trend

d Multivariate models adjusted for BM blast percentage, immunophenotype, WBC count, risk group, t(12;21)(p13;q22) rearrangement, high hyperdiploidy, age and gender